STERIS Xodus Medical Acquisition: $2.1B Deal Explained

The STERIS Xodus Medical acquisition is a $2.1 billion bet on the unglamorous but steady part of surgery: the disposable products that keep patients safe on the operating table. On 12 October 2026, STERIS announced that it will buy Xodus Medical, a Pennsylvania maker of patient positioning systems and other surgical safety products, with the deal expected to close by 31 December 2026.

The price is large for a company that expects about $245 million of revenue this year. This report sets out the terms, the numbers behind the valuation, what Xodus makes, why STERIS wants it and what the parties have not said.

STERIS Xodus Medical acquisition: the deal terms

• Price: $2.1 billion at closing, subject to customary adjustments.
• Earnout: up to $150 million more, tied to performance targets in calendar 2028.
• Tax benefits: about $300 million in net present value of cash tax benefits, which STERIS says brings the net price to roughly $1.8 billion. Both are company estimates.
• Structure: STERIS Corporation, a wholly owned subsidiary of STERIS plc, will acquire all the equity of Xodus Medical and certain related affiliates.
• Financing: primarily debt. The amount and terms were not disclosed.
• Closing: expected by 31 December 2026, subject to customary conditions and regulatory approvals.
• Advisers: Goldman Sachs and Jones Day for STERIS, and J.P. Morgan and Morgan, Lewis and Bockius for Xodus.

The timetable is short. An announcement in mid-October and a target close before the end of December leaves about eleven weeks for regulatory review and closing conditions, which suggests the parties do not expect a lengthy competition review. That is our reading, not a statement from either company.

The numbers behind the STERIS Xodus Medical acquisition

The companies gave projections for calendar 2026: revenue of about $245 million, operating income of $121 million and adjusted EBIT of about $135 million, after adding back about $14 million of charges, mostly from a royalty arrangement that ended in 2026. These are forecasts, not audited results.

By our calculation, $2.1 billion is about 8.6 times projected revenue, or 7.3 times on the $1.8 billion net price. Against adjusted EBIT, it is about 15.6 times gross and 13.3 times net. The projected margins are unusually high for a medical products maker: operating income is about 49% of revenue, and adjusted EBIT about 55%. If the earnout is paid in full, the headline price could reach $2.25 billion, and the expected tax benefit is about 14% of the closing price. All of these ratios are our own arithmetic on company projections.

Why does the gap between operating income and adjusted EBIT matter? Because the add-back of about $14 million rests on a royalty arrangement that has been terminated, so the adjustment only holds if that cost genuinely disappears. Readers should treat the adjusted figure as the company’s framing and the $121 million operating income as the more conservative base.

What Xodus Medical makes in the STERIS Xodus Medical acquisition

Founded in 1993 and based near Pittsburgh, Xodus describes itself as a developer and maker of devices for surgical patient safety. Its flagship product is the Pink Pad patient positioning system, which supports patients on the operating table, and its portfolio includes other proprietary surgical safety technologies and operating-room consumables. The release says the business has grown at double-digit rates, with a steady stream of new products, but gives no historical figures. The owner of Xodus and the seller were not named in the material we reviewed.

Why STERIS wants Xodus: the STERIS Xodus Medical acquisition rationale

STERIS is known for sterilisation and infection prevention products and services, and its chief executive, Dan Carestio, says the Xodus portfolio complements and expands its offering, particularly in operating-room consumables. Consumables are bought repeatedly, which makes revenue steadier than one-off equipment sales, and in our assessment that is the main appeal. The STERIS Xodus Medical acquisition also puts the company closer to the surgical team, which already buys its products. Xodus chief executive Craig Kaforey called the company an established provider of solutions that measurably improve surgical patient safety. Both are company statements, not independent findings.

What the STERIS Xodus Medical acquisition leaves unanswered

• Debt and leverage: how much STERIS will borrow, on what terms, and what it does to its balance sheet.
• Earnings effect: the release says the deal will add to growth, margins and adjusted earnings, but gives no figure or timeline for GAAP earnings per share.
• Synergies: none were quantified.
• Seller and ownership: not stated.
• Regulatory review: approvals are mentioned only in general terms. US merger filings are handled under the Federal Trade Commission’s premerger notification programme and recorded in the SEC’s EDGAR database.
• Outlook: STERIS will provide a revised fiscal 2027 outlook including Xodus after closing.

Our assessment of the STERIS Xodus Medical acquisition

In our assessment, the price is high but reflects a business that, on the company’s own numbers, is both growing and exceptionally profitable. The risks sit in the details the release leaves out: how much debt STERIS takes on, whether the forecast margins hold, and whether the earnout aligns the sellers with delivery. Surgical consumables are also a closely watched cost for hospitals worldwide, and pricing pressure is a recurring theme, as in our report on trade margins on cancer drugs in India. The release has no India-specific information. For other recent deals, see our reports on the Viatris and Pacira acquisition, Axogen’s BioCircuit purchase and BD’s $19 billion US manufacturing plan, or browse more medical device news.

What to watch after the STERIS Xodus Medical acquisition

• Regulatory clearance and the closing date.
• STERIS’s financing details and revised fiscal 2027 outlook.
• Xodus’s results against the 2026 projections.
• Any further deals in operating-room consumables.

Frequently asked questions

How much is the STERIS Xodus Medical acquisition worth?

$2.1 billion at closing, plus up to $150 million in earnouts. STERIS estimates about $1.8 billion net of tax benefits.

What does Xodus Medical make?

Surgical patient safety products, including the Pink Pad patient positioning system and operating-room consumables.

When will the STERIS Xodus Medical acquisition close?

STERIS expects to close it by 31 December 2026, subject to regulatory approvals.

How is it being paid for?

Primarily with debt, according to the announcement.

Who is selling Xodus in the STERIS Xodus Medical acquisition?

The announcement does not name the seller.

How we reported this: we relied on the parties’ announcement of 12 October 2026 and on coverage of the same terms. Projections and estimates are the companies’. Figures labelled as ours are our own calculations. Last updated: 13 October 2026. This article is news reporting and not investment advice.